Arcellx(ACLX)
Focus: Arcellx is a publicly traded biotechnology company focused on adaptive immune cell therapies for oncology, headquartered in Redwood City, CA. The company was acquired by Gilead for $7.8 billion in April 2026.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Arcellx
AI assessmentNot HiringNo open roles listed right now. Follow Arcellx to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Arcellx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$110M
Pipeline & Clinical Trials
SPRX002
Acute Myeloid LeukemiaClinical Trials (1)
NCT05457010Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1Help build intelligence for Arcellx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.